Literature DB >> 34003611

Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis.

Xianwen Hu1, Yan Wu1, Peiqing Yang1, Ju Wang1, Pan Wang1, Jiong Cai1.   

Abstract

OBJECTIVE: To explore the feasibility of 68Ga-PSMA PET/CT in diagnosing primary prostate cancer.
MATERIALS AND METHODS: Embase, PubMed and Cochrane Library databases were searched for studies published before July 2020. The studies that used 68Ga-PSMA PET/CT for detecting primary prostate cancer, and pathological biopsy as the reference standard were included. The selecting process used preferred reporting items for systematic reviews and meta-analyses (PRISMA). The quality of enrolled studies was assessed by the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool.
RESULTS: According to our search strategy, 9 studies were included for analysis. A total of 547 patients with primary prostate cancer and 443 lesion segments that underwent 68Ga-PSMA PET/CT scans were included and their pathological biopsies were compared. The results of these studies showed some differences. For instance, the lowest sensitivity of 68Ga-PSMA PET/CT in diagnosing primary prostate cancer was 67%, while the highest sensitivity recorded was 97%.
CONCLUSIONS: Compared with conventional imaging examinations, 68Ga-PSMA PET/CT had higher sensitivity and specificity in detecting primary prostate cancer. At present, most of the studies that used 68Ga-PSMA PET/CT for detecting prostate cancer are retrospective studies. Based on its advantage of high detection rate, the use of 68Ga-PSMA PET/CT in the detection of primary prostate cancer is worthy of promotion. Copyright® by the International Brazilian Journal of Urology.

Entities:  

Keywords:  Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen ; Prostatic Neoplasms

Mesh:

Substances:

Year:  2022        PMID: 34003611     DOI: 10.1590/S1677-5538.IBJU.2020.0986

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   3.050


  1 in total

1.  Virtual Prostate Biopsy with Prostate-specific Membrane Antigen and Magnetic Resonance Imaging: Closer to Reality in a Subgroup of Prostate Cancer Patients?

Authors:  Kelsey L Pomykala; Ken Herrmann; Louise Emmett; Elisabetta Lalumera; Stefano Fanti
Journal:  Eur Urol Open Sci       Date:  2022-08-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.